Erleada (apalutamide) vs Nubeqa (darolutamide)

Erleada (apalutamide) and Nubeqa (darolutamide) are both non-steroidal androgen receptor inhibitors used in the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC). While both medications work by blocking the effect of androgens (like testosterone) to slow the growth of prostate cancer, they differ in their chemical structure and pharmacokinetics. It is important for a patient to discuss with their healthcare provider the potential side effects, drug interactions, and the specific clinical profile of each medication, including any individual health considerations, to determine which drug is the most appropriate for their treatment plan.

Difference between Erleada and Nubeqa

Metric	Erleada (apalutamide)	Nubeqa (darolutamide)
Generic name	Apalutamide	Darolutamide
Indications	Non-metastatic castration-resistant prostate cancer (nmCRPC), metastatic castration-sensitive prostate cancer (mCSPC)	Non-metastatic castration-resistant prostate cancer (nmCRPC)
Mechanism of action	Androgen receptor inhibitor	Androgen receptor inhibitor
Brand names	Erleada	Nubeqa
Administrative route	Oral	Oral
Side effects	Fatigue, hypertension, rash, diarrhea, nausea, weight loss, arthralgia, falls, hot flush, decreased appetite, fractures, and peripheral edema	Fatigue, pain in extremity, rash, decreased white blood cell count, and increased liver enzymes
Contraindications	Pregnancy, severe hepatic impairment	Pregnancy, severe hepatic impairment
Drug class	Nonsteroidal antiandrogen	Nonsteroidal antiandrogen
Manufacturer	Janssen Biotech	Bayer

Efficacy

Introduction to Erleada (apalutamide)

Erleada (apalutamide) is a medication that has been approved for the treatment of prostate cancer. Specifically, it is indicated for the treatment of non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-sensitive prostate cancer (mCSPC). Apalutamide works by inhibiting the action of androgens, which are male hormones that can promote tumor growth in the prostate gland. This mechanism of action helps to slow the progression of the disease and can improve survival rates for patients.

Efficacy of Erleada in Clinical Trials

The efficacy of Erleada for nmCRPC was demonstrated in the SPARTAN trial, a randomized clinical study that compared apalutamide plus androgen deprivation therapy (ADT) with placebo plus ADT. The primary endpoint was metastasis-free survival (MFS), and the results showed a significant improvement in MFS for patients taking Erleada. For mCSPC, the TITAN trial showed that adding apalutamide to ADT significantly improved overall survival and radiographic progression-free survival compared to placebo plus ADT. These findings established Erleada as an effective treatment option for patients with nmCRPC and mCSPC.

Introduction to Nubeqa (darolutamide)

Nubeqa (darolutamide) is another medication approved for the treatment of prostate cancer, specifically nmCRPC. Darolutamide is an androgen receptor inhibitor that blocks the effect of androgens, thereby inhibiting the growth of prostate cancer cells. Its unique chemical structure is designed to minimize the crossing of the blood-brain barrier, potentially reducing the risk of central nervous system side effects. This feature is particularly important for maintaining the quality of life in patients undergoing treatment for prostate cancer.

Efficacy of Nubeqa in Clinical Trials

The efficacy of Nubeqa was evaluated in the ARAMIS trial, which was a multicenter, double-blind, placebo-controlled study. In this study, patients with nmCRPC were randomized to receive either darolutamide or a placebo, in addition to ADT. The primary endpoint was MFS, and the results demonstrated a significant extension in MFS for patients treated with Nubeqa compared to the placebo group. Additionally, secondary endpoints such as time to pain progression and overall survival were also improved with Nubeqa treatment, confirming its role as an effective option for patients with nmCRPC.

Regulatory Agency Approvals

Erleada

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA
Health Canada
Therapeutic Goods Administration (TGA), Australia

Nubeqa

European Medical Agency (EMA), European Union
Food and Drug Administration (FDA), USA

Access Erleada or Nubeqa today

If Erleada or Nubeqa are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

Buy Erleada

Buy Nubeqa

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email: